Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:37 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 539730 | NSE: FREDUN

Fredun Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,026.07Overvalued by 40.21%vs CMP ₹1,716.00

P/E (27.6) × ROE (15.8%) × BV (₹294.00) × DY (0.04%)

₹852.80Overvalued by 50.30%vs CMP ₹1,716.00
MoS: -101.2% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,407.4924%Over (-18%)
Graham NumberEarnings₹677.8017%Over (-60.5%)
DCFCash Flow₹1,211.9211%Over (-29.4%)
Net Asset ValueAssets₹288.748%Over (-83.2%)
EV/EBITDAEnterprise₹981.3510%Over (-42.8%)
Dividend DiscountDividends₹38.5010%Over (-97.8%)
Earnings YieldEarnings₹694.508%Over (-59.5%)
ROCE CapitalReturns₹568.678%Over (-66.9%)
Revenue MultipleRevenue₹833.336%Over (-51.4%)
Consensus (9 models)₹852.80100%Overvalued
Key Drivers: EPS CAGR 37.2% lifts DCF — verify sustainability. | Wide model spread (₹39–₹1,407) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 37.2%

*Investments are subject to market risks

Investment Snapshot

73
Fredun Pharmaceuticals Ltd scores 73/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health64/100 · Moderate
ROCE 18.9% GoodROE 15.8% GoodD/E 0.92 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money85/100 · Strong
FII holding up 1.06% (6mo) AccumulatingDII holding up 1.30% MF buyingPromoter holding at 43.1% Stable
Earnings Quality65/100 · Strong
OPM expanding (8% → 12%) Improving
Quarterly Momentum90/100 · Strong
Revenue (4Q): +46% YoY AcceleratingProfit (4Q): +89% YoY Strong
Industry Rank75/100 · Strong
P/E 27.6 vs industry 53.8 Cheaper than peersROCE 18.9% vs industry 16.4% Average3Y sales CAGR: 27% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:37 am

Market Cap 939 Cr.
Current Price 1,716
Intrinsic Value₹852.80
High / Low 1,999/635
Stock P/E27.6
Book Value 294
Dividend Yield0.04 %
ROCE18.9 %
ROE15.8 %
Face Value 10.0
PEG Ratio0.74

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Fredun Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Fredun Pharmaceuticals Ltd 939 Cr. 1,716 1,999/63527.6 2940.04 %18.9 %15.8 % 10.0
Fermenta Biotech Ltd 965 Cr. 328 399/24110.9 1330.76 %23.0 %24.9 % 5.00
Syncom Formulations (India) Ltd 1,050 Cr. 11.2 23.5/10.215.2 4.000.00 %18.6 %15.5 % 1.00
Wanbury Ltd 805 Cr. 230 330/16218.7 18.10.00 %36.7 %76.5 % 10.0
TTK Healthcare Ltd 1,107 Cr. 784 1,402/73515.9 7681.28 %9.26 %6.89 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Fredun Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 788062828711879107103167120145161
Expenses 7168547276107689389150103123135
Operating Profit 712810111110141317172226
OPM % 9%15%12%12%12%9%13%13%13%10%14%15%16%
Other Income 0000000000000
Interest 24334445587811
Depreciation 1111111111122
Profit before tax 584666687891314
Tax % 25%51%41%32%27%13%25%44%25%12%25%25%25%
Net Profit 342445445771010
EPS in Rs 7.668.585.248.418.9810.768.759.0411.2914.9714.3420.6119.53

Last Updated: March 3, 2026, 9:48 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 5:20 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 212542576097113134222275348456593
Expenses 202438535487104126208247310401510
Operating Profit 1243610881428385583
OPM % 7%7%9%6%10%11%7%6%6%10%11%12%14%
Other Income 0012001122100
Interest 1122234459142233
Depreciation 1111112223446
Profit before tax 01223623918212844
Tax % 47%52%42%36%34%28%24%37%26%38%27%26%
Net Profit 00112422611162134
EPS in Rs 1.021.114.556.085.1111.184.765.0414.3023.8533.2244.0769.45
Dividend Payout % 0%0%13%10%12%6%14%14%5%3%2%2%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%100.00%100.00%-50.00%0.00%200.00%83.33%45.45%31.25%
Change in YoY Net Profit Growth (%)0.00%100.00%0.00%-150.00%50.00%200.00%-116.67%-37.88%-14.20%

Fredun Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:34%
5 Years:32%
3 Years:27%
TTM:36%
Compounded Profit Growth
10 Years:54%
5 Years:61%
3 Years:49%
TTM:35%
Stock Price CAGR
10 Years:%
5 Years:41%
3 Years:4%
1 Year:64%
Return on Equity
10 Years:13%
5 Years:13%
3 Years:15%
Last Year:16%

Last Updated: September 5, 2025, 3:30 pm

Balance Sheet

Last Updated: March 3, 2026, 2:59 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 2222344445555
Reserves 0012193537396492117137153
Borrowings 791621101935405387106166171
Other Liabilities 811243047476579667481179136
Total Liabilities 1823435679105141162187257308487464
Fixed Assets 781516163131303239475365
CWIP 01041100000000
Investments 0000000000122
Other Assets 111429365274110131155218260433397
Total Assets 1823435679105141162187257308487464

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -1234171-110-2-14-0-29
Cash from Investing Activity + -2-3-6-7-8-5-1-1-4-9-8-6
Cash from Financing Activity + 2133-8414-1725638
Net Cash Flow -001-1102-211-23
Free Cash Flow -2-1-3-39-4-12-1-7-24-8-35
CFO/OP -48%108%85%117%303%8%-128%2%-17%-52%-1%-52%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-6.00-7.00-12.00-18.00-4.00-9.00-27.00-32.00-39.00-59.00-68.00-111.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 59759813194671261121484668142
Inventory Days 1071021406817024922724296264246265
Days Payable 15216722122436020520821510110488160
Cash Conversion Cycle 141117-24-96110145139144205225247
Working Capital Days -44-54-44-39426665116126979276
ROCE %14%14%25%18%16%21%10%10%13%18%17%19%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Feb 2026
Promoters 49.62%49.31%49.16%49.17%49.17%48.93%48.93%48.93%48.93%48.93%43.06%43.06%
FIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.46%1.06%
DIIs 1.64%1.60%1.60%1.60%1.60%1.59%1.59%1.59%1.59%1.61%3.48%2.89%
Public 48.74%49.08%49.24%49.24%49.23%49.47%49.47%49.47%49.49%49.46%53.00%52.99%
No. of Shareholders 4,6256,3136,8377,5077,5118,0188,1217,9767,9068,1208,7658,443

Shareholding Pattern Chart

No. of Shareholders

Fredun Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 44.8333.6624.1311.285.05
Diluted EPS (Rs.) 44.8333.3222.9311.285.05
Cash EPS (Rs.) 53.4941.3230.0419.1610.07
Book Value[Excl.RevalReserv]/Share (Rs.) 299.47258.49212.64153.54107.96
Book Value[Incl.RevalReserv]/Share (Rs.) 299.47258.49212.64153.54107.96
Dividend / Share (Rs.) 0.700.700.700.700.70
Revenue From Operations / Share (Rs.) 961.13740.88606.04506.38335.60
PBDIT / Share (Rs.) 116.6982.7865.3134.8026.41
PBIT / Share (Rs.) 107.2774.7059.1129.9321.39
PBT / Share (Rs.) 59.8745.6538.6319.408.04
Net Profit / Share (Rs.) 44.0733.2523.8414.295.05
PBDIT Margin (%) 12.1411.1710.776.877.86
PBIT Margin (%) 11.1610.089.755.916.37
PBT Margin (%) 6.226.166.373.832.39
Net Profit Margin (%) 4.584.483.932.821.50
Return on Networth / Equity (%) 14.7112.8611.219.304.67
Return on Capital Employeed (%) 31.7824.9317.7211.7111.35
Return On Assets (%) 4.275.074.203.381.24
Long Term Debt / Equity (X) 0.060.100.500.610.67
Total Debt / Equity (X) 1.180.860.890.770.92
Asset Turnover Ratio (%) 1.141.231.241.290.90
Current Ratio (X) 1.311.542.042.071.50
Quick Ratio (X) 0.570.490.621.440.72
Inventory Turnover Ratio (X) 2.191.752.513.111.71
Dividend Payout Ratio (NP) (%) 1.582.092.884.8913.30
Dividend Payout Ratio (CP) (%) 1.301.682.283.656.67
Earning Retention Ratio (%) 98.4297.9197.1295.1186.70
Cash Earning Retention Ratio (%) 98.7098.3297.7296.3593.33
Interest Coverage Ratio (X) 2.462.853.193.302.53
Interest Coverage Ratio (Post Tax) (X) 1.932.142.162.361.76
Enterprise Value (Cr.) 477.16441.23435.36456.41223.45
EV / Net Operating Revenue (X) 1.051.271.592.031.67
EV / EBITDA (X) 8.6611.3414.7129.5921.21
MarketCap / Net Operating Revenue (X) 0.690.961.281.811.38
Retention Ratios (%) 98.4197.9097.1195.1086.69
Price / BV (X) 2.232.773.665.964.29
Price / Net Operating Revenue (X) 0.690.961.281.811.38
EarningsYield 0.060.040.030.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Fredun Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 08/06/1987 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1987PLC043662 and registration number is 043662. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 453.82 Cr. and Equity Capital is Rs. 4.72 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsURMI ESTATE, 11th Floor, Mumbai Maharashtra 400013Contact not found
Management
NamePosition Held
Dr.(Mrs.) Daulat N MedhoraChairman & Jt. M. D
Mr. Fredun MedhoraManaging Director & CFO
Mrs. Daisy D�souzaInd. Non-Executive Director
Mr. Anshu AgarwalInd. Non-Executive Director
Dr. Rohinton KangaInd. Non-Executive Director
Dr. Aspi RaimalwalaInd. Non-Executive Director
Mrs. Sonal DesaiInd. Non-Executive Director

FAQ

What is the intrinsic value of Fredun Pharmaceuticals Ltd and is it undervalued?

As of 12 April 2026, Fredun Pharmaceuticals Ltd's intrinsic value is ₹852.80, which is 50.30% lower than the current market price of ₹1,716.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (15.8 %), book value (₹294), dividend yield (0.04 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd is trading at ₹1,716.00 as of 12 April 2026, with a FY2026-2027 high of ₹1,999 and low of ₹635. The stock is currently near its 52-week high. Market cap stands at ₹939 Cr..

How does Fredun Pharmaceuticals Ltd's P/E ratio compare to its industry?

Fredun Pharmaceuticals Ltd has a P/E ratio of 27.6, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Fredun Pharmaceuticals Ltd financially healthy?

Key indicators for Fredun Pharmaceuticals Ltd: ROCE of 18.9 % indicates efficient capital utilization; ROE of 15.8 % shows strong shareholder returns. Dividend yield is 0.04 %.

Is Fredun Pharmaceuticals Ltd profitable and how is the profit trend?

Fredun Pharmaceuticals Ltd reported a net profit of ₹21 Cr in Mar 2025 on revenue of ₹456 Cr. Compared to ₹6 Cr in Mar 2022, the net profit shows an improving trend.

Does Fredun Pharmaceuticals Ltd pay dividends?

Fredun Pharmaceuticals Ltd has a dividend yield of 0.04 % at the current price of ₹1,716.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Fredun Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports